Imunofan during endometrial cancer treatment and rehabilitation
Comparison in people · 2004
- What was studied
- 220 patients with endometrial cancer in the Tver report. 120 received adjunctive Imunofan, and the remainder formed the comparison group.
- Main finding
- Radiation complications · Reported 12.7% lower with Imunofan (p<0.05). Absolute rates and the denominator for this difference were not supplied.
Reported findings and study design
Reported findings
Intramuscular Imunofan before surgery, during radiotherapy and every six months during rehabilitation. Dose per injection, injection counts and allocation methods were not reported.
Population or model 220 patients with endometrial cancer in the Tver report. 120 received adjunctive Imunofan, and the remainder formed the comparison group.
Dose, route and schedule
Intramuscular Imunofan before surgery, during radiotherapy and every six months during rehabilitation. Dose per injection, injection counts and allocation methods were not reported.
Protocol source ↗ · Original conference abstract II.13.62. Its figures are not assigned to the 2001 Venediktova journal report.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Radiation complications | Reported 12.7% lower with Imunofan (p<0.05). Absolute rates and the denominator for this difference were not supplied. | |
| Karnofsky performance assessment | The proportion with high scores was reported as 21.8% higher (p<0.05). Absolute rates and the threshold for a high score were unavailable. | |
| Mortality and survival | The authors reported one-year mortality 9.8% lower and a trend toward 8% higher five-year survival. Event counts, uncertainty and an adjusted comparison were unavailable. | |
| Lymphocyte recovery and tolerability | Reported about 1.5 times faster lymphocyte recovery (p<0.05). The abstract states no negative side effects and gives no systematic safety data. |
The brief report omits treatment allocation, baseline prognosis, raw event counts and whether the percentage differences are absolute or relative. The survival observations cannot establish a causal effect. Venediktova also published a 2001 endometrial cancer report involving Imunofan and Tactivin. Participant overlap is unresolved, so the two reports should not be added as independent cohorts.
Source for these results ↗ · Reviewed 2026-11-14
Study limitations and source details
Study limitations
- The brief report omits treatment allocation, baseline prognosis, raw event counts and whether the percentage differences are absolute or relative. The survival observations cannot establish a causal effect.
- Venediktova also published a 2001 endometrial cancer report involving Imunofan and Tactivin. Participant overlap is unresolved, so the two reports should not be added as independent cohorts.
Related publications may describe some of the same participants or experiments.
Source details
Original conference abstract
Original conference abstract II.13.62. Its figures are not assigned to the 2001 Venediktova journal report.
Sources checked
Added to the library
Citation
N. N. Gladkova, M. A. Demidova, M. G. Venediktova. Imunofan during endometrial cancer treatment and rehabilitation Palliative Medicine and Rehabilitation, 2004, issue 2, conference abstract II.13.62.